At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SINO BIOPHARM
Market Closed 11-22 16:08:13
3.300
-0.080
-2.37%
High3.430Low3.260Vol42.39M
Open3.360D1 Closing3.380Amplitude5.03%
Mkt Cap62.01BTradable Cap62.01BTotal Shares18.79B
T/O140.58MT/O Rate0.23%Tradable Shares18.79B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Sino Biopharmaceutical Submits New Indication Application for Liver Cancer Drug Combo
MT Newswires Live  ·  11-21 15:03
Sino Biopharmaceutical Submits New Indication Application for Liver Cancer Drug Combo
Sino Biopharmaceutical - Submitted a New Indication Application for Marketing to Cde for Anlotinib Hydrochloride Capsule
THOMSON REUTERS  ·  11-21 12:07
Sino Biopharmaceutical - Submitted a New Indication Application for Marketing to Cde for Anlotinib Hydrochloride Capsule
Sino Biopharm Injects 142 Million Yuan into LaNova Medicines
MT Newswires Live  ·  11-20 18:51
Sino Biopharm Injects 142 Million Yuan into LaNova Medicines
Greater China Stocks Close Mixed; Shanghai Leads Gainers
Dow Jones  ·  11-20 15:30
Greater China Stocks Close Mixed; Shanghai Leads Gainers
BUZZ-Sino Biopharmaceutical rises most in nearly 5 weeks on LaNova deal
Reuters  ·  11-20
BUZZ-Sino Biopharmaceutical rises most in nearly 5 weeks on LaNova deal
BRIEF-Sino Biopharmaceutical Signs Equity Investment And Strategic Cooperation Agreement
Reuters  ·  11-20
BRIEF-Sino Biopharmaceutical Signs Equity Investment And Strategic Cooperation Agreement
Sino Biopharmaceutical - Signing Equity Investment and Strategic Cooperation Agreement With Lanova Medicines
THOMSON REUTERS  ·  11-20
Sino Biopharmaceutical - Signing Equity Investment and Strategic Cooperation Agreement With Lanova Medicines
Sino Biopharmaceutical - Deal for Lm-108 in Mainland China Region
THOMSON REUTERS  ·  11-20
Sino Biopharmaceutical - Deal for Lm-108 in Mainland China Region
Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod
MT Newswires Live  ·  11-15
Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod
BRIEF-Sino Biopharmaceutical Says Approval Granted For EGFR Inhibitor "TQB3002"
Reuters  ·  11-14
BRIEF-Sino Biopharmaceutical Says Approval Granted For EGFR Inhibitor "TQB3002"
Sino Biopharmaceutical - Approval Granted for Clinical Trials of Egfr Inhibitor "Tqb3002" in US
THOMSON REUTERS  ·  11-14
Sino Biopharmaceutical - Approval Granted for Clinical Trials of Egfr Inhibitor "Tqb3002" in US
The five-year shareholder returns and company earnings persist lower as Sino Biopharmaceutical (HKG:1177) stock falls a further 4.0% in past week
Simply Wall St.  ·  11-12
The five-year shareholder returns and company earnings persist lower as Sino Biopharmaceutical (HKG:1177) stock falls a further 4.0% in past week
Sino Biopharmaceutical Cancer Drug Gets Marketing Approval in China
MT Newswires Live  ·  11-11
Sino Biopharmaceutical Cancer Drug Gets Marketing Approval in China
BRIEF-Sino Biopharmaceutical Approval For Marketing Of Kras G12c Inhibitor Garsorasib Tablet From Nmpa
Reuters  ·  11-11
BRIEF-Sino Biopharmaceutical Approval For Marketing Of Kras G12c Inhibitor Garsorasib Tablet From Nmpa
Sino Biopharmaceutical - Approval for Marketing of Kras G12c Inhibitor Garsorasib Tablet From Nmpa
THOMSON REUTERS  ·  11-11
Sino Biopharmaceutical - Approval for Marketing of Kras G12c Inhibitor Garsorasib Tablet From Nmpa
Greater China Stocks Rise; Shanghai Sees Largest Increase
Dow Jones  ·  11-04
Greater China Stocks Rise; Shanghai Sees Largest Increase
BRIEF-Sino Biopharmaceutical Says Acquisition Of 29.99% Equity Interest In Hob Biotech
Reuters  ·  10-31
BRIEF-Sino Biopharmaceutical Says Acquisition Of 29.99% Equity Interest In Hob Biotech
BRIEF-Sino Biopharmaceutical Posts Qtrly Profit Attributable Of RMB1.15 Bln
Reuters  ·  10-30
BRIEF-Sino Biopharmaceutical Posts Qtrly Profit Attributable Of RMB1.15 Bln
Sino Biopharmaceutical - Qtrly Profit Attributable RMB1.15 Bln
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Qtrly Profit Attributable RMB1.15 Bln
Sino Biopharmaceutical - Beijing Runkang Agreed to Acquire 29.99% Stake in Hob Biotech Group
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Beijing Runkang Agreed to Acquire 29.99% Stake in Hob Biotech Group

Introduction

Company Name.
SINO BIOPHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.
Issue price:
--